Gilead’s Kite, Arcellx Expand BCMA CAR-T Partnership Into Lymphomas
Executive Summary
The amendment to a December 2022 deal expands their myeloma CAR-T partnership and will see development of CART-ddBCMA in lymphomas, where research indicates anti-BCMA therapy has activity.